"Gene Therapy For Dopamine Transporter Deficiency Syndrome" in Patent Application Approval Process (USPTO 20240115737).
In: Gene Therapy Weekly, 2024-05-02, S. 2283-2283
serialPeriodical
Zugriff:
A patent application has been filed for a gene therapy approach to treat Dopamine Transporter Deficiency Syndrome (DTDS), a parkinsonian disorder caused by mutations in the SLC6A3 gene. The therapy involves using a vector, such as an AAV or lentiviral vector, to introduce a promoter linked to the human SLC6A3 gene, which encodes the dopamine transporter protein. This vector can target dopaminergic neurons to address the impaired function of the dopamine transporter. The patent application provides detailed information on the specific sequences and serotypes that can be used in the vector, and includes claims related to the use of the vector in therapy. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
"Gene Therapy For Dopamine Transporter Deficiency Syndrome" in Patent Application Approval Process (USPTO 20240115737).
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2024-05-02, S. 2283-2283 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Schlagwort: |
|
Sonstiges: |
|